Picomole doses of platelet-activating factor predispose the gastric mucosa to damage by topical irritants
- PMID: 3726156
- DOI: 10.1016/0090-6980(86)90028-6
Picomole doses of platelet-activating factor predispose the gastric mucosa to damage by topical irritants
Abstract
The ability of the endogenous pro-inflammatory phospholipid, platelet-activating factor (Paf), to increase the susceptibility of the rat gastric mucosa to damage induced by a topical irritant was studied in an ex vivo gastric chamber model. Intravenous infusion of Paf (1-100 ng/kg/min) for 5 minutes dose-dependently increased the haemorrhagic damage induced by topically applied 20% ethanol. The pro-ulcerogenic actions of Paf were not solely due to its hypotensive actions, since a significant augmentation of damage was observed with doses of Paf (1 ng/kg/min) which did not affect systemic arterial blood pressure. These pro-ulcerogenic actions were not shared by the structurally similar precursor/breakdown product, lyso-Paf (100 ng/kg/min). Paf (100 ng/kg/min) also significantly increased the gastric damage induced by topically applied 2 mM sodium taurocholate. Infusion of Paf for 5 minutes without topical irritation only caused significant gastric damage at the highest dose tested (100 ng/kg/min). Histologically, this damage was characterized by extensive vasocongestion, deep mucosal necrosis, swelling of the gastric glands and accumulations of neutrophils in the mucosal and submucosal venules. Paf is thus a potent pro-ulcerogenic agent in the gastric mucosa. The endogenous release of Paf during septic shock or inflammatory diseases of the gastrointestinal tract could contribute to the mucosal injury associated with these disorders.
Similar articles
-
Gastric mucosal damage induced by local intra-arterial administration of Paf in the rat.Br J Pharmacol. 1988 Jan;93(1):222-8. doi: 10.1111/j.1476-5381.1988.tb11425.x. Br J Pharmacol. 1988. PMID: 3349230 Free PMC article.
-
Microvascular actions of platelet-activating factor on rat gastric mucosa and submucosa.Am J Physiol. 1986 Dec;251(6 Pt 1):G772-8. doi: 10.1152/ajpgi.1986.251.6.G772. Am J Physiol. 1986. PMID: 3789144
-
Potent ulcerogenic actions of platelet-activating factor on the stomach.Nature. 1986 Jan 2-8;319(6048):54-6. doi: 10.1038/319054a0. Nature. 1986. PMID: 3510396
-
Role of leukotrienes and platelet activating factor in gastric mucosal damage and repair.J Physiol Pharmacol. 1991 Jun;42(2):107-33. J Physiol Pharmacol. 1991. PMID: 1782413 Review.
-
Gastric effects of PAF.Methods Find Exp Clin Pharmacol. 1989;11 Suppl 1:61-6. Methods Find Exp Clin Pharmacol. 1989. PMID: 2657290 Review.
Cited by
-
Gastric cytoprotection: a critical appraisal of the concept, methodology, implications, mechanisms and future research prospects.Agents Actions. 1987 Oct;22(1-2):114-22. doi: 10.1007/BF01968826. Agents Actions. 1987. PMID: 3318322 Review.
-
Thirteenth Gaddum Memorial Lecture. Neuronal and endothelium-derived mediators in the modulation of the gastric microcirculation: integrity in the balance.Br J Pharmacol. 1993 Sep;110(1):3-17. doi: 10.1111/j.1476-5381.1993.tb13763.x. Br J Pharmacol. 1993. PMID: 8220892 Free PMC article. Review. No abstract available.
-
Failure of prostaglandin E2 and its 16,16-dimethyl analogue to prevent the gastric mucosal damage induced by Paf.Br J Pharmacol. 1987 Feb;90(2):365-71. doi: 10.1111/j.1476-5381.1987.tb08966.x. Br J Pharmacol. 1987. PMID: 3470106 Free PMC article.
-
Spatial heterogeneity of mucosal blood flow during ischemia-reperfusion injury of rat stomach investigated by laser Doppler perfusion imaging.J Gastroenterol. 1995 Jun;30(3):279-86. doi: 10.1007/BF02347500. J Gastroenterol. 1995. PMID: 7647892
-
Effects of inhibitors of arachidonic acid metabolism on Paf-induced gastric mucosal necrosis and haemoconcentration.Br J Pharmacol. 1986 Oct;89(2):415-22. doi: 10.1111/j.1476-5381.1986.tb10275.x. Br J Pharmacol. 1986. PMID: 3096408 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources